- Canadian MED company Tilray reported a loss of $17.9M, more than analysts anticipated. While cannabis investors are increasingly concerned on profitability, Tilray CEO Brendan Kennedy said, “You’d be constraining yourself if you were focused on profitability at this point.”
- One analyst called Tilray’s quarter a “disaster” and advised avoiding the stock “until industry rationalization occurs.”
- MarketWatch calls unprofitable early acquisitions a “time bomb” on many of the largest Canadian companies’ balance sheets.
- At New Cannabis Ventures, Alan Brochstein explains why he’s still not a fan of cannabis exchange traded funds (ETFs).